Olivier Martinon, DVM, MS

Olivier M. Martinon, DVM, MS, is Vice President, External Innovation & Research Alliances at Zoetis. In this role he is leading a team identifying and evaluating potential sources for new products (and enabling technologies) worldwide, as well as establishing long term relationships with academic organizations and biotechs.

Since joining Zoetis in 2006 (after being New Antigen Department head for Merial EU & US), Olivier has held a variety of roles, including leading the BioPharma initiative in Zoetis. For a decade, he managed the biotherapeutic portfolio, including monoclonal antibodies, proteins and peptides. Olivier led the development of CYTOPOINT, the monoclonal treatment for atopic dermatitis in dogs that is now registered around the world. He is also leading the development of LIBRELA, already approved in Europe as the first monoclonal anti-NGF antibody registered for alleviation of osteoarthritis-related pain.

Olivier received his DVM from École nationale vétérinaire d'Alfort and DEA/MS “Biotechnology & Molecular Biology” degree from Pierre and Marie Curie Paris VI University. He has also been trained in immunology & virology for 3 years.

Personally, Olivier grew-up in Lyon, France and moved to U.S. as an expatriate in 2002 and is now French and American citizen. He is married to Nathalie, they share three grown sons.